MXPA05006123A - Analogos de quinazolin-4-ilamina 2-sustituida como moduladores de receptores de capsaicina. - Google Patents
Analogos de quinazolin-4-ilamina 2-sustituida como moduladores de receptores de capsaicina.Info
- Publication number
- MXPA05006123A MXPA05006123A MXPA05006123A MXPA05006123A MXPA05006123A MX PA05006123 A MXPA05006123 A MX PA05006123A MX PA05006123 A MXPA05006123 A MX PA05006123A MX PA05006123 A MXPA05006123 A MX PA05006123A MX PA05006123 A MXPA05006123 A MX PA05006123A
- Authority
- MX
- Mexico
- Prior art keywords
- receptor modulators
- capsaicin receptor
- substituted quinazolin
- ylamine analogues
- ligands
- Prior art date
Links
- -1 2-substituted quinazolin-4-ylamine Chemical class 0.000 title abstract 2
- 102000011040 TRPV Cation Channels Human genes 0.000 title 1
- 108010062740 TRPV Cation Channels Proteins 0.000 title 1
- 102000005962 receptors Human genes 0.000 abstract 3
- 108020003175 receptors Proteins 0.000 abstract 3
- 241001465754 Metazoa Species 0.000 abstract 2
- 239000003446 ligand Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000004913 activation Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 244000144972 livestock Species 0.000 abstract 1
- 230000004807 localization Effects 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
- C07F9/65128—Six-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Otolaryngology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Anesthesiology (AREA)
- Pregnancy & Childbirth (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Tropical Medicine & Parasitology (AREA)
Abstract
Se proporcionan ciertos analogos de quinazolin-4-ilamina 2-sustituida. Estos compuestos son ligandos que se pueden utilizar in vitro o in vivo, para modular la actividad de receptores especificos y son particularmente utiles en el tratamiento de condiciones asociadas con la activacion de receptores patologicos en humanos, animales domesticos de compania y ganado. Ser proporcionan composiciones farmaceuticas y metodos para utilizarlas en el tratamiento de estos trastornos, como son los metodos para utilizar estos ligandos para estudios de localizacion de receptores.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43313902P | 2002-12-13 | 2002-12-13 | |
PCT/US2003/039606 WO2004055003A1 (en) | 2002-12-13 | 2003-12-12 | 2-substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA05006123A true MXPA05006123A (es) | 2005-09-30 |
Family
ID=32595121
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA05006123A MXPA05006123A (es) | 2002-12-13 | 2003-12-12 | Analogos de quinazolin-4-ilamina 2-sustituida como moduladores de receptores de capsaicina. |
Country Status (13)
Country | Link |
---|---|
US (2) | US7432275B2 (es) |
EP (2) | EP1569925A1 (es) |
JP (2) | JP2006515847A (es) |
KR (1) | KR20050084292A (es) |
CN (1) | CN1726205A (es) |
AR (1) | AR042461A1 (es) |
AU (2) | AU2003300898A1 (es) |
BR (1) | BR0317168A (es) |
CA (2) | CA2509233A1 (es) |
MX (1) | MXPA05006123A (es) |
PE (1) | PE20040935A1 (es) |
TW (1) | TW200418480A (es) |
WO (2) | WO2004055003A1 (es) |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2280003B1 (en) | 2002-07-15 | 2014-04-02 | Symphony Evolution, Inc. | Process for preparing receptor-type kinase modulators |
EP1569925A1 (en) * | 2002-12-13 | 2005-09-07 | Neurogen Corporation | 2-substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators |
EP1581225A1 (en) * | 2002-12-13 | 2005-10-05 | Neurogen Corporation | Combination therapy for the treatment of pain |
CN1820007A (zh) * | 2003-07-10 | 2006-08-16 | 神经能质公司 | 经芳基取代的苯并[d]异噻唑-3-基胺类似物 |
TW200510373A (en) * | 2003-07-14 | 2005-03-16 | Neurogen Corp | Substituted quinolin-4-ylamine analogues |
US7329664B2 (en) | 2003-07-16 | 2008-02-12 | Neurogen Corporation | Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues |
AU2004270740A1 (en) * | 2003-09-09 | 2005-03-17 | Neurogen Corporation | 4 - heterobicyclyamino - substituted quinazolines and analogues therof as capsaicin - antagonists |
SI2213661T1 (sl) | 2003-09-26 | 2011-11-30 | Exelixis Inc | c-Met modulatorji in postopki uporabe |
MXPA06008257A (es) * | 2004-01-23 | 2006-08-31 | Amgen Inc | Ligandos del receptor vanilloide y su uso en tratamientos. |
CA2555867A1 (en) * | 2004-03-04 | 2005-09-22 | Neurogen Corporation | Arylalkylamino-substituted quinazoline analogues |
CA2557852A1 (en) * | 2004-04-08 | 2005-10-27 | Neurogen Corporation | Substituted cinnolin-4-ylamines |
EP1771162B1 (en) * | 2004-07-19 | 2013-06-05 | Xenia Pharma | Capsaicin inhibitors for the treatment of obesity-related disorders |
TW200621251A (en) * | 2004-10-12 | 2006-07-01 | Neurogen Corp | Substituted biaryl quinolin-4-ylamine analogues |
US20060128710A1 (en) * | 2004-12-09 | 2006-06-15 | Chih-Hung Lee | Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof |
GB0428475D0 (en) * | 2004-12-30 | 2005-02-02 | 4 Aza Bioscience Nv | Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders |
CN101232885A (zh) * | 2005-01-25 | 2008-07-30 | 神经能质公司 | 经取代的哒嗪基喹啉-4-基胺和嘧啶基喹啉-4-基胺类似物 |
KR20060087386A (ko) | 2005-01-28 | 2006-08-02 | 주식회사 대웅제약 | 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물 |
US8232278B2 (en) | 2005-06-24 | 2012-07-31 | Gilead Sciences, Inc. | Pyrido(3,2-D)pyrimidines and pharmaceutical compositions useful for treating hepatitis C |
ATE449097T1 (de) * | 2005-07-21 | 2009-12-15 | Hoffmann La Roche | Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer |
EP1790342A1 (de) | 2005-11-11 | 2007-05-30 | Zentaris GmbH | Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege |
US8217042B2 (en) | 2005-11-11 | 2012-07-10 | Zentaris Gmbh | Pyridopyrazines and their use as modulators of kinases |
CN101360746B (zh) * | 2005-11-22 | 2013-12-11 | 库多斯药物有限公司 | 作为mTOR抑制剂的吡啶并-、吡唑并-和嘧啶并-嘧啶衍生物 |
WO2007076034A2 (en) * | 2005-12-21 | 2007-07-05 | Abbott Laboratories | Anti-viral compounds |
EP1971611B1 (en) | 2005-12-21 | 2012-10-10 | Abbott Laboratories | Anti-viral compounds |
EP2345652A1 (en) | 2005-12-21 | 2011-07-20 | Abbott Laboratories | Antiviral compounds |
ATE475660T1 (de) | 2005-12-21 | 2010-08-15 | Abbott Lab | Antivirale verbindungen |
WO2007081978A2 (en) * | 2006-01-11 | 2007-07-19 | Angion Biomedica Corporation | Modulators of hepatocyte growth factor / c-met activity |
US8338435B2 (en) | 2006-07-20 | 2012-12-25 | Gilead Sciences, Inc. | Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections |
WO2008057300A2 (en) * | 2006-10-27 | 2008-05-15 | Redpoint Bio Corporation | Trpvi antagonists and uses thereof |
EP2094276A4 (en) | 2006-12-20 | 2011-01-05 | Abbott Lab | ANTIVIRAL COMPOUNDS |
TW200840584A (en) | 2006-12-26 | 2008-10-16 | Gilead Sciences Inc | Pyrido(3,2-d)pyrimidines useful for treating viral infections |
US20090209536A1 (en) * | 2007-06-17 | 2009-08-20 | Kalypsys, Inc. | Aminoquinazoline cannabinoid receptor modulators for treatment of disease |
ES2539290T3 (es) | 2008-04-18 | 2015-06-29 | Daewoong Pharmaceutical Co., Ltd. | Un derivado novedoso de benzoxazina bencimidazol, una composición farmacéutica que comprende el mismo y su uso |
WO2009130900A1 (ja) * | 2008-04-24 | 2009-10-29 | 日本曹達株式会社 | オキシム誘導体、中間体化合物および植物病害防除剤 |
AU2009268547A1 (en) * | 2008-07-11 | 2010-01-14 | Myrexis, Inc. | Pharmaceutical compounds as cytotoxic agents and the use thereof |
WO2010029996A1 (ja) * | 2008-09-11 | 2010-03-18 | 協和発酵キリン株式会社 | 医薬組成物 |
US8703962B2 (en) * | 2008-10-24 | 2014-04-22 | Purdue Pharma L.P. | Monocyclic compounds and their use as TRPV1 ligands |
US8546388B2 (en) * | 2008-10-24 | 2013-10-01 | Purdue Pharma L.P. | Heterocyclic TRPV1 receptor ligands |
US8759362B2 (en) * | 2008-10-24 | 2014-06-24 | Purdue Pharma L.P. | Bicycloheteroaryl compounds and their use as TRPV1 ligands |
EP2387563B2 (en) | 2009-01-16 | 2022-04-27 | Exelixis, Inc. | Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quinolin-4-yl]oxy}phenyl-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
DK2401267T3 (en) | 2009-02-27 | 2014-03-10 | Ambit Biosciences Corp | JAK-kinase modulating quinazoline derivatives AND THEIR APPLICATION IN PROCESSES |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
AR079814A1 (es) * | 2009-12-31 | 2012-02-22 | Otsuka Pharma Co Ltd | Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos |
ES2581840T3 (es) * | 2010-09-01 | 2016-09-07 | Ambit Biosciences Corporation | Pirazolilaminoquinazolina ópticamente activa y composiciones farmacéuticas y métodos de uso de la misma |
WO2012030948A1 (en) | 2010-09-01 | 2012-03-08 | Ambit Biosciences Corporation | Quinazoline compounds and methods of use thereof |
WO2012031383A1 (zh) * | 2010-09-06 | 2012-03-15 | 中国科学院广州生物医药与健康研究院 | 酰胺类化合物 |
SI2621481T2 (sl) | 2010-09-27 | 2023-02-28 | Exelixis, Inc., | Dvojni inhibitorji MET in VEGF za zdravljenje proti kastraciji odpornega raka prostate in osteoblastnih kostnih metastaz |
KR101293384B1 (ko) | 2010-10-13 | 2013-08-05 | 주식회사 대웅제약 | 신규 피리딜 벤조옥사진 유도체, 이를 포함하는 약학 조성물 및 이의 용도 |
JP5872585B2 (ja) | 2010-12-22 | 2016-03-01 | パーデュー、ファーマ、リミテッド、パートナーシップ | リン置換キノキサリンタイプピペリジン化合物とその使用 |
BR112013020874A2 (pt) | 2011-02-18 | 2019-05-21 | Endo Pharmaceuticals Inc. | composto, regime, método para a preparação do referido composto, e, uso de um composto |
KR20140048216A (ko) * | 2011-06-29 | 2014-04-23 | 오츠카 세이야쿠 가부시키가이샤 | 치료 화합물로서의 퀴나졸린 및 관련된 사용 방법 |
JP6121658B2 (ja) * | 2011-06-29 | 2017-04-26 | 大塚製薬株式会社 | 治療用化合物、及び関連する使用の方法 |
US9044482B2 (en) | 2012-08-15 | 2015-06-02 | Asana Biosciences, Llc | Use of aminoindane compounds in treating overactive bladder and interstitial cystitis |
WO2017031427A1 (en) * | 2015-08-19 | 2017-02-23 | 3-V Biosciences, Inc. | COMPOUNDS AND METHODS FOR INHIBITING mTOR |
WO2017147146A1 (en) * | 2016-02-23 | 2017-08-31 | Concentric Analgesics, Inc. | Prodrugs of phenolic trpv1 agonists |
CA3025377A1 (en) | 2016-06-02 | 2017-12-07 | Abbvie Inc. | Glucocorticoid receptor agonist and immunoconjugates thereof |
US10239875B2 (en) | 2017-06-16 | 2019-03-26 | King Saud University | Naphthyridinyl hydrazine derivatives as potent peripheral analgesic agents |
JP7448472B2 (ja) * | 2017-10-09 | 2024-03-12 | ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド | カリウムイオンチャネル及びtrpv1チャネルのモジュレーター、並びにその使用 |
RU2020117698A (ru) | 2017-12-01 | 2022-01-04 | Эббви Инк. | Агонист глюкокортикоидного рецептора и его иммуноконъюгаты |
WO2020132553A1 (en) * | 2018-12-21 | 2020-06-25 | Sorrento Therapeutics, Inc. | Perineural administration of resiniferatoxin for treatment of maladaptive pain |
WO2021257857A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Naphthyridinone compounds as jak2 v617f inhibitors |
WO2021257863A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
EP4175719A1 (en) | 2020-07-02 | 2023-05-10 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
WO2022046989A1 (en) | 2020-08-27 | 2022-03-03 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Alk﹘5抑制劑和彼之用途 |
US11919908B2 (en) | 2020-12-21 | 2024-03-05 | Incyte Corporation | Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors |
AR125273A1 (es) | 2021-02-25 | 2023-07-05 | Incyte Corp | Lactamas espirocíclicas como inhibidores de jak2 v617f |
CA3237199A1 (en) | 2021-11-02 | 2023-05-11 | Flare Therapeutics Inc. | Pparg inverse agonists and uses thereof |
WO2023141522A2 (en) * | 2022-01-21 | 2023-07-27 | Slap Pharmaceuticals Llc | Multicyclic compounds |
WO2023141661A1 (en) * | 2022-01-24 | 2023-07-27 | Inter-Med, Inc. | Dental material compositions for cleansing and removal of anionic contaminants from substrates & their methods of use |
DE102022104759A1 (de) | 2022-02-28 | 2023-08-31 | SCi Kontor GmbH | Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3501696A1 (de) * | 1985-01-19 | 1986-07-24 | Bayer Ag, 5090 Leverkusen | Pyridopyrimidine, mehrere verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
EP0326307B1 (en) * | 1988-01-23 | 1994-08-17 | Kyowa Hakko Kogyo Co., Ltd. | Novel pyridazinone derivatives and pharmaceutical preparations containing them |
GB8910722D0 (en) * | 1989-05-10 | 1989-06-28 | Smithkline Beckman Intercredit | Compounds |
GB8928281D0 (en) | 1989-12-14 | 1990-02-21 | Smith Kline French Lab | Compounds |
DE4131029A1 (de) * | 1991-09-18 | 1993-07-29 | Basf Ag | Substituierte pyrido (2,3-d) pyrimidine als antidots |
AU661533B2 (en) * | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
GB9323290D0 (en) * | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
TW263498B (es) | 1993-11-10 | 1995-11-21 | Takeda Pharm Industry Co Ltd | |
US6395733B1 (en) | 1995-06-07 | 2002-05-28 | Pfizer Inc | Heterocyclic ring-fused pyrimidine derivatives |
AR004010A1 (es) * | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
GB9603097D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline compounds |
HRP970371A2 (en) * | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
DE69718472T2 (de) * | 1996-07-13 | 2003-11-06 | Glaxo Group Ltd | Bicyclische heteroaromatische verbindungen als protein tyrosine kinase inhibitoren |
AR007857A1 (es) * | 1996-07-13 | 1999-11-24 | Glaxo Group Ltd | Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen. |
US6225318B1 (en) * | 1996-10-17 | 2001-05-01 | Pfizer Inc | 4-aminoquinazolone derivatives |
IL129825A0 (en) * | 1996-11-27 | 2000-02-29 | Pfizer | Fused bicyclic pyrimidine derivatives |
WO1998038984A2 (en) * | 1997-03-05 | 1998-09-11 | Sugen, Inc. | Formulations for hydrophobic pharmaceutical agents |
US5939421A (en) | 1997-07-01 | 1999-08-17 | Signal Pharmaceuticals, Inc. | Quinazoline analogs and related compounds and methods for treating inflammatory conditions |
US6251912B1 (en) * | 1997-08-01 | 2001-06-26 | American Cyanamid Company | Substituted quinazoline derivatives |
GB9800569D0 (en) * | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
GB2345486A (en) * | 1999-01-11 | 2000-07-12 | Glaxo Group Ltd | Heteroaromatic protein tyrosine kinase inhibitors |
CN1391562A (zh) | 1999-09-21 | 2003-01-15 | 阿斯特拉曾尼卡有限公司 | 用作药物的喹唑啉衍生物 |
JP3868811B2 (ja) | 1999-10-01 | 2007-01-17 | 大日本住友製薬株式会社 | 新規キナゾリン誘導体 |
MXPA03000458A (es) | 2000-07-20 | 2004-06-02 | Neurogen Corp | Ligandos receptores de capsaicina. |
DE60128709T2 (de) | 2000-09-15 | 2007-12-27 | Vertex Pharmaceuticals Inc., Cambridge | Triazol-verbindungen als protein-kinase-inhibitoren |
PL373484A1 (en) * | 2001-12-10 | 2005-09-05 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
AU2002358700A1 (en) | 2001-12-26 | 2003-07-15 | Bayer Aktiengesellschaft | Urea derivatives as vr1- antagonists |
BR0306982A (pt) * | 2002-01-17 | 2004-10-26 | Neurogen Corp | Composto ou um sal deste farmaceuticamente aceitável, composição farmacêutica, métodos para reduzir a condutância de cálcio de um receptor da capsaicina celular, para inibir a ligação de ligando vanilóide a um receptor da capsaicina in vitro e em um paciente, para tratar uma condição responsiva à modulação do receptor da capsaicina em um paciente, para tratar a dor em um paciente, para tratar coceira em um paciente, para tratar tosse ou soluço em um paciente, promover a perda de peso em um paciente obeso, e para determinar a presença ou ausência de receptor da capsaicina em uma amostra, preparação farmacêutica embalada, e, uso de um composto |
WO2003097586A1 (en) | 2002-05-17 | 2003-11-27 | Janssen Pharmaceutica N.V. | Aminotetralin-derived urea modulators of vanilloid vr1 receptor |
ES2355472T3 (es) * | 2002-05-22 | 2011-03-28 | Amgen Inc. | Derivados de aminopirimidina para su uso como ligandos del receptor vaniloide para el tratamiento del dolor. |
WO2004028440A2 (en) | 2002-09-24 | 2004-04-08 | Bayer Healthcare Ag | Vr1 antagonists for the treatment of urological disorders |
EP1569925A1 (en) * | 2002-12-13 | 2005-09-07 | Neurogen Corporation | 2-substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators |
EP1575918A2 (en) * | 2002-12-19 | 2005-09-21 | Neurogen Corporation | Substituted biaryl-4-carboxylic acid arylamide analogues as capsaicin receptor modulators |
TW200510373A (en) * | 2003-07-14 | 2005-03-16 | Neurogen Corp | Substituted quinolin-4-ylamine analogues |
US7329664B2 (en) * | 2003-07-16 | 2008-02-12 | Neurogen Corporation | Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues |
AU2004270740A1 (en) * | 2003-09-09 | 2005-03-17 | Neurogen Corporation | 4 - heterobicyclyamino - substituted quinazolines and analogues therof as capsaicin - antagonists |
AU2004285052A1 (en) * | 2003-10-31 | 2005-05-12 | Neurogen Corporation | 4-amino (AZA) quinoline derivatives as capsaicin receptor agonists |
TW200621251A (en) * | 2004-10-12 | 2006-07-01 | Neurogen Corp | Substituted biaryl quinolin-4-ylamine analogues |
AU2006204752A1 (en) * | 2005-01-14 | 2006-07-20 | Neurogen Corporation | Heteroaryl substituted quinolin-4-ylamine analogues |
-
2003
- 2003-12-12 EP EP03813410A patent/EP1569925A1/en not_active Withdrawn
- 2003-12-12 MX MXPA05006123A patent/MXPA05006123A/es not_active Application Discontinuation
- 2003-12-12 JP JP2004560828A patent/JP2006515847A/ja not_active Withdrawn
- 2003-12-12 BR BR0317168-0A patent/BR0317168A/pt not_active Application Discontinuation
- 2003-12-12 EP EP03813411A patent/EP1569926A1/en not_active Withdrawn
- 2003-12-12 TW TW092135120A patent/TW200418480A/zh unknown
- 2003-12-12 US US10/539,031 patent/US7432275B2/en not_active Expired - Fee Related
- 2003-12-12 CA CA002509233A patent/CA2509233A1/en not_active Abandoned
- 2003-12-12 CA CA002509239A patent/CA2509239A1/en not_active Abandoned
- 2003-12-12 KR KR1020057010845A patent/KR20050084292A/ko not_active Application Discontinuation
- 2003-12-12 JP JP2004560827A patent/JP2006515846A/ja not_active Withdrawn
- 2003-12-12 WO PCT/US2003/039606 patent/WO2004055003A1/en active Application Filing
- 2003-12-12 CN CNA2003801058156A patent/CN1726205A/zh active Pending
- 2003-12-12 AU AU2003300898A patent/AU2003300898A1/en not_active Abandoned
- 2003-12-12 WO PCT/US2003/039607 patent/WO2004055004A1/en active Application Filing
- 2003-12-12 AU AU2003296984A patent/AU2003296984A1/en not_active Abandoned
- 2003-12-12 US US10/735,607 patent/US20040156869A1/en not_active Abandoned
- 2003-12-12 AR ARP030104607A patent/AR042461A1/es unknown
-
2004
- 2004-01-05 PE PE2004000034A patent/PE20040935A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AR042461A1 (es) | 2005-06-22 |
US20040156869A1 (en) | 2004-08-12 |
EP1569925A1 (en) | 2005-09-07 |
US20060089354A1 (en) | 2006-04-27 |
EP1569926A1 (en) | 2005-09-07 |
WO2004055004A1 (en) | 2004-07-01 |
AU2003300898A1 (en) | 2004-07-09 |
CA2509239A1 (en) | 2004-07-01 |
WO2004055004A8 (en) | 2005-07-21 |
WO2004055003A1 (en) | 2004-07-01 |
JP2006515846A (ja) | 2006-06-08 |
TW200418480A (en) | 2004-10-01 |
KR20050084292A (ko) | 2005-08-26 |
CN1726205A (zh) | 2006-01-25 |
PE20040935A1 (es) | 2005-01-01 |
US7432275B2 (en) | 2008-10-07 |
JP2006515847A (ja) | 2006-06-08 |
CA2509233A1 (en) | 2004-07-01 |
BR0317168A (pt) | 2005-11-01 |
AU2003296984A1 (en) | 2004-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA05006123A (es) | Analogos de quinazolin-4-ilamina 2-sustituida como moduladores de receptores de capsaicina. | |
TW200510373A (en) | Substituted quinolin-4-ylamine analogues | |
MY145822A (en) | Substituted biaryl piperazinyl-pyridine analogues | |
WO2006081388A3 (en) | Substituted pyridazinyl-and pyrimidinyl-quinolin-4-ylamine analogues | |
TW200621251A (en) | Substituted biaryl quinolin-4-ylamine analogues | |
WO2005007648A3 (en) | Biaryl piperazinyl-pyridine analogues | |
MY148461A (en) | Heteroaryl amide analogues as p2x7 antagonists | |
WO2006078992A3 (en) | Heteroaryl substituted piperazinyl-pyridine analogues | |
WO2006076646A3 (en) | Heteroaryl substituted quinolin-4-ylamine analogues | |
MY150731A (en) | Heteroaryl amide derivatives | |
WO2004056774A3 (en) | Substituted biphenyl-4-carboxylic acid arylamide analogues as capsaicin receptor modulators | |
PH12014501677A1 (en) | 5-membered heterocyclic amides and related compounds | |
NO20043411L (no) | Substituerte quinazolin-4-ylamin analoger | |
WO2005023807A3 (en) | 4 - heterobicyclyamino - substituted quinazolines and analogues therof as capsaicin - antagonists | |
WO2005042498A3 (en) | 4-amino (aza) quinoline derivatives as capsaicin receptor agonists | |
WO2005084401A3 (en) | Aryl substituted purine analogues | |
WO2007101007A3 (en) | Aryl sulfonyl heterocycles | |
WO2007140383A3 (en) | Spirocyclic sulfonamides and related compounds | |
WO2008024433A3 (en) | Haloalkyl-substituted pyrimidinone derivatives | |
SG155958A1 (en) | Aryl-substituted piperazine derivatives | |
WO2008024438A3 (en) | 2-phenoxy pyrimidinone analogues | |
WO2006071538A3 (en) | Substituted biaryl analogues | |
WO2008033739A3 (en) | Benzimidazole carboxamide derivatives | |
WO2005084368A3 (en) | Heteroalkyl-substituted biphenyl-4-carboxylic acid arylamide analogues | |
WO2008066664A3 (en) | Cis-cyclohexyl substituted pyrimidinone derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |